Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Therapeutics

Background:

• RNA interference (RNAi) utilizes small interfering RNA (siRNA) for sequence-specific gene silencing, offering therapeutic potential for diseases driven by aberrant gene activity.
• Current siRNA therapeutics face challenges in clinical translation due to poor biological stability and inefficient delivery, despite advances with cationic lipid and polymer carriers.
• Existing cationic nanocarriers for siRNA delivery exhibit limitations including non-specific protein adsorption, excessive liver accumulation, and significant toxicity, hindering clinical application.

Approach:

• Carrier-free bioconjugation of siRNA with biocompatible molecules like lipids, peptides, antibodies, aptamers, and polymers is explored.
• Molecularly engineered siRNA conjugates are designed to enhance pharmacokinetic properties and improve delivery efficiency.
• This strategy aims to enable RNAi delivery to target tissues beyond the liver, overcoming current therapeutic limitations.

Key Points:

• Molecularly engineered siRNA conjugates represent a promising strategy to overcome the limitations of traditional siRNA delivery systems.
• These conjugates facilitate targeted delivery of RNAi payloads to specific tissues, including tumors, for enhanced therapeutic efficacy.
• The carrier-free approach minimizes toxicity associated with nanocarrier-based delivery systems.

Conclusions:

• Molecularly engineered siRNA conjugates offer a viable path for advancing RNAi-based therapies from the laboratory to clinical practice.
• This approach broadens the therapeutic potential of RNAi beyond liver-targeted treatments, opening new avenues for disease management.
• Further research into siRNA conjugation strategies is crucial for realizing the full clinical potential of RNAi therapeutics for various diseases, particularly cancer.